Owner GP Pharm S.A.

Service Spruson & Ferguson

Filing Date 1 March 2012

Class 5 Pharmaceutical preparations for human use including pharmaceuticals for use in nighttime or daytime enuresis, Willebrand-Jurgen's syndrome, hemorrhaging, diabetes insipidus, for use in oncology, for treating cancer, for treating cardiovascular diseases, antivirals, for treating inflammatory diseases of the intestine, for treating inflammatory diseases of the connective tissue, for treating arthritis, for treating urological diseases, for treating psychiatric diseases, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, for treating neurological and neurodegenerative diseases and disorders, dementia linked to Alzheimer's disease, Huntington's disease, Parkinson's disease, cerebral palsy, brain injuries and diseases, injuries and diseases of the spinal cord, convulsive disorders, epilepsy, encephalitis, disorders of the central nervous system, ocular motility disorders, dystonia, blepharospasm, strabismus, facial scoliosis and tics, cerebral ischemia, dementia, amyotrophic sclerosis, and lateral multiple sclerosis, for treating auto-immune diseases, for treating transplant rejection, for treating ophthalmological diseases such as proliferative or non-proliferative diabetic retinopathy, macular degeneration, age-related macular degeneration, retinal neovascularization, neovascularization associated with choroidal melanoma, retinopathy, central retinal vein occlusion, pigmentary retinitis, uveitis, macular edema, cystoid macular edema, peptides